Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by BENDEX, G.
Right arrow Articles by BJELLE, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BENDEX, G.
Right arrow Articles by BJELLE, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 British Society for Rheumatology

research-article

ADDING LOW-DOSE CYCLOSPORIN A TO PARENTERAL GOLD THERAPY IN RHEUMATOID ARTHRITIS: A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY

G. BENDEX and A. BJELLE

Department of Rheumatology, Gothenburg University Linneplatsen 8, 413 10 Gothenburg, Sweden

Correspondence to: Correspondence to: A. Bjellc, Department of Rheumatology, Gothenburg University, Linnéplatsen 8, 413 10 Gothenburg, Sweden

A double-blind, randomized comparison between parenteral gold therapy (PGT) and cyclosporin A (CyA) vs PGT and placebo during 6 months was performed in 40 RA patients experiencing a decreasing effect of ongoing PGT. Patients' overall assessment of health was the only efficacy variable significantly better in the CyA- and PGT-treated vs the placebo- and PGT-treated group. Higher blood pressure and more signs of renal impairment were found during the 6 months treatment in the former compared with the latter group. Six months after the end of the combination therapy, a higher potassium value in the CyA-treated group was the only difference. In conclusion, no effects additional to those expected with single-drug therapy or additional risks of side-effects of either drug were found when combining low-dose CyA with ongoing PGT in RA patients with long disease duration.

KEY WORDS: Drug therapy, Combination, Gold sodium thiomalate, Cyclosporin A, Arthritis, Rheumatoid


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
E. H. S. Choy, C. Smith, C. J. Dore, and D. L. Scott
A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal
Rheumatology, November 1, 2005; 44(11): 1414 - 1421.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.